SCINTIX therapy uses signals from the cancer itself, generated in real time, to autonomously deliver a tracked dose that handles both expected and unexpected tumor and patient motion.
Finally, SCINTIX therapy solves the decades-old conundrum of tumor motion by using radiopharmaceutical emissions to generate live targeting data continuously updated with sub second latency during treatment. RefleXion’s SCINTIX technology is the first self-driving radiotherapy where the cancer autonomously directs its own treatment.
The RefleXion platform enables clinicians to treat multiple tumors in a single treatment plan. Dose is jointly optimized and evaluated across all targets and organs-at-risk simultaneously. With hybrid treatments, clinicians can combine both SCINTIX and SBRT targets into a single plan and have the flexibility to choose the best therapy for each target.
The RefleXion platform is designed to deliver SCINTIX autonomous radiotherapy along with industry-leading CT-guided IMRT and SBRT. Equipped with exquisite fan-beam kVCT imaging, the RefleXion platform provides exceptional imaging for patient setup during delivery, resulting in improved confidence for accurate dose delivery. Additionally, the high-quality kVCT images create a foundation for future adaptive tools with superior target delineation and dosimetric calculations.
SCINTIX technology converges radiation oncology and nuclear medicine to create the first theranostic approach for external-beam radiotherapy. We believe it will establish a new standard of care for patients with metastatic disease driven by discovery in the nuclear medicine industry of novel radiotracers that have increased disease specificity. SCINTIX therapy advances personalized medicine by using the molecular characteristics of each tumor to target radiation delivery on the day of treatment.
Let us tell you more.
Contact UsStay up to date.
Sign Up